Growth Metrics

Supernus Pharmaceuticals (SUPN) Long-Term Investments (2016 - 2024)

Historic Long-Term Investments for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q1 2024 value amounting to $11.7 million.

  • Supernus Pharmaceuticals' Long-Term Investments fell 7846.63% to $11.7 million in Q1 2024 from the same period last year, while for Mar 2024 it was $11.7 million, marking a year-over-year decrease of 7846.63%. This contributed to the annual value of $16.6 million for FY2023, which is 8230.28% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Long-Term Investments of $11.7 million as of Q1 2024, which was down 7846.63% from $16.6 million recorded in Q4 2023.
  • In the past 5 years, Supernus Pharmaceuticals' Long-Term Investments registered a high of $534.7 million during Q1 2020, and its lowest value of $11.7 million during Q1 2024.
  • For the 5-year period, Supernus Pharmaceuticals' Long-Term Investments averaged around $215.4 million, with its median value being $131.9 million (2022).
  • Its Long-Term Investments has fluctuated over the past 5 years, first soared by 2420.03% in 2021, then crashed by 8230.28% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Long-Term Investments (Quarter) stood at $350.4 million in 2020, then crashed by 65.99% to $119.2 million in 2021, then dropped by 21.21% to $93.9 million in 2022, then tumbled by 82.3% to $16.6 million in 2023, then fell by 29.82% to $11.7 million in 2024.
  • Its last three reported values are $11.7 million in Q1 2024, $16.6 million for Q4 2023, and $25.1 million during Q3 2023.